JNJ Add to watchlist
$257.77 +0.00 (+0.00%)
Pre-Market: $253.85 3.92 (-1.52%)
Last updated: Jul 15, 2026 10:00
52-Week Range
$253.85
$154.80 $253.85 $269.43

Fundamentals Overview

Johnson & Johnson is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 29.5 P/B 7.65 P/S 6.34

Intrinsic value (DCF)

+28.9% upside vs price

Profitability

Net margin 21.8%

Risk (Beta)

0.24 — lower vol

Earnings & growth

EPS $8.60 Rev -2% Profit +2.3% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 72% confidence Risk: Lower Volatility — Beta 0.24. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +28.9% upside vs price · Analyst grade: B+ · Sentiment improving (2 upgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$611.07B
P/E (TTM)
29.5
EPS (TTM)
$8.60
Dividend Yield
2.06%
52-Week Range
$154.80 - $269.43
Volume vs Avg
N/A
Beta
0.24

About

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories....
Sector: Healthcare
Headquarters: US
Employees: 141,700
IPO Date: Jan 1962
Website: www.jnj.com
Beta: 0.24 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Equal Weight: 4, Hold: 4, Market Perform: 1, Neutral: 3, Outperform: 4, Overweight: 5, Sector Outperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $327.09; current price is $253.85. That’s a +28.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 29.5
DCF value (model) $327.09 (28.9% upside)
PEG (TTM) N/A
P/B (TTM) 7.65
P/S (TTM) 6.34
P/FCF (TTM) 34.33
Liquidity & enterprise
Current Ratio (TTM) 1.03
Quick Ratio (TTM) 0.77
Cash Ratio (TTM) 0.38
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 21.83%
Gross margin (TTM) 69.12%
Operating margin (TTM) 26.87%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for JNJ.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Equal Weight 4Hold 4Market Perform 1Neutral 3Outperform 4Overweight 5Sector Outperform 1
2 upgrades, 0 downgrades
Price Target Consensus
Current $253.85
Median $265.00
Consensus $262.17
Low consensus $220.00
High consensus $290.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
RBC Capital maintain Outperform Outperform 2026-07-13
TD Cowen maintain Buy Buy 2026-07-13
B of A Securities maintain Neutral Neutral 2026-07-10
Morgan Stanley maintain Overweight Overweight 2026-07-08
Citigroup maintain Buy Buy 2026-07-08
Guggenheim maintain Buy Buy 2026-06-26
Leerink Partners upgrade Market Perform Outperform 2026-05-13
Wells Fargo maintain Overweight Overweight 2026-04-15
Stifel maintain Hold Hold 2026-04-15
Barclays maintain Equal Weight Equal Weight 2026-04-15
Morgan Stanley maintain Overweight Overweight 2026-04-10
RBC Capital maintain Outperform Outperform 2026-03-30
Barclays maintain Equal Weight Equal Weight 2026-03-19
HSBC maintain Buy Buy 2026-03-17
Citigroup maintain Buy Buy 2026-03-11
JP Morgan maintain Neutral Neutral 2026-03-05
RBC Capital maintain Outperform Outperform 2026-02-03
Morgan Stanley upgrade Equal Weight Overweight 2026-01-28
Freedom Broker maintain Hold Hold 2026-01-27
Freedom Capital Markets maintain Hold Hold 2026-01-27
Guggenheim maintain Buy Buy 2026-01-23
B of A Securities maintain Neutral Neutral 2026-01-22
Citigroup maintain Buy Buy 2026-01-22
Scotiabank maintain Sector Outperform Sector Outperform 2026-01-22
TD Cowen maintain Buy Buy 2026-01-22
Wells Fargo maintain Overweight Overweight 2026-01-22
Morgan Stanley maintain Equal Weight Equal Weight 2026-01-22
Stifel maintain Hold Hold 2026-01-22
Bernstein maintain Market Perform Market Perform 2026-01-09
Barclays maintain Equal Weight Equal Weight 2025-12-30